Other

Chugai Seiyaku Kabushiki Kaisha

Tadamitsu Kishimoto

Ajinomoto Co., Ltd.

Shionogi Company Limited

Ono Pharmaceutical Co., Ltd.

University of California

Tosoh Corporation

Otsuka Pharmaceutical Company, Limited

Ono Pharmaceuticals Co., Ltd.

Kishimoto, Tadamitsu

Masuda, Kazuya

Toshio Hirano

Hiroaki Ito

Akira Okano

Norihiro Nishimoto

Yukio Akiyama

Shizuo Akira

Hiroshi Matsui

Hidetomo Kitamura

Yoshiyuki Takahara

Mitoshi Konno

Masamichi Sugimoto

Kenichi Akamatsu

Kazuyuki Yoshizaki

Mikio Konishi

Shin Shimaoka

Takashi Nagasawa

Kazunobu Tachibana

Toshihiro Nakajima

Yuichi Yamamura

Kazuya Masuda

Masahiko Mihara

Osamu Yoshie

Yoshiyuki Ohsugi

Nobuo Katsube

Hiroshi Isshiki

Yoichiro Moriya

Hideo Kimura

Toshiyuki Ishibashi

Shigemi Kinoshita

Osamu Tanabe

Takuya Shimamoto

Mitsunari Yamamoto

Hisashi Iizasa

Nobuaki Yoshida

Tetsuji Naka

Takashi Saito

Hiroshi Suzuki

Satoru Nakai

Daisuke Miki

Kiyoshi Yasukawa

Yoshikatsu Hirai

Katsuhito Sakaki

Masao Naka

Steven A Miles

Hideko Nakahara

Ronald H Stevens

Otoniel M Martinez

David J Klashman

Yasuo Adachi

Koichi Takayama

Yasuo LabI R Grad School F Biosc Adachi

Provided are a therapeutic and/or prophylactic agent for a lung disease and a method for screening for the therapeutic and/or prophylactic agent. Provided are a therapeutic and/or prophylactic agent for a lung disease comprising an Arid5A inhibitor as an active ingredient and a method for screening for the therapeutic and/or prophylactic agent.

Therapeutic agent for a lung disease and/or method for screening for the same

The present invention provides a mesothelioma therapeutic agent containing an interleukin-6 (IL-6) antagonist such as antibody to IL-6 receptor (IL-6R), and a mesothelioma cell growth inhibitor containing an IL-6 antagonist such as antibody to IL-6R.

Mesothelioma therapeutic agent

To provide a preventive and/or therapeutic agent for vasculitis such as polyarteritis nodosa, the aortitis syndrome, and a vasculitis that is associated with immunological abnormalities, said agent comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

Treatment of vasculitis with IL-6 antagonist

A method for treating psoriasis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.

Method for treating psoriasis by administering an antibody to interleukin-6 receptor

A method for treating psoriatic arthritis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.

Method of treating psoriatic arthritis with an IL-6 receptor antibody

This invention provides a therapeutic agent for inhibiting neovascularization, a therapeutic agent for a solid cancer, a therapeutic agent for a disease pathologically caused by neovascularization, and a therapeutic agent for repairing a tissue comprising as the effective ingredient, a substance that potentiates the action of CXCR4. Based on the finding that vascularization is suppressed in CXCR4 knockout mice, it becomes possible to prepare a therapeutic agent for suppressing vascularization, a therapeutic agent for a solid cancer, a therapeutic agent for a disease pathologically caused by neovascularization, each of which comprises as the effective ingredient, a substance that inhibits the action of CXCR4, as well as to prepare a therapeutic agent for repairing a tissue comprising as the effective ingredient, a substance that potentiates the action of CXCR4. Methods for treatment are made possible that use these therapeutic agents.

Inhibiting vascularization using antibodies to CXCR4 and SDF-1

There is provided a synovial cell growth inhibitor, or a pharmaceutical composition for treatment of chronic rheumatoid arthritis based on the synovial cell growth inhibitor. The pharmaceutical composition for treatment of chronic rheumatoid arthritis or synovial cell growth inhibitor contains an IL-6 antagonist, such as IL-6 antibody or IL-6R antibody, as an effective component.

Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component

A preventive or therapeutic agent for inflammatory bowel disease such as Crohn's disease and ulcerative colitis said agent comprising as an active ingredient an interleukin-6 (IL-6) antagonist such as an antibody directed against IL-6 receptor.

Preventive or therapeutic agent for inflammatory bowel disease comprising IL-6 antagonist as an active ingredient

The present invention pertains to a DNA encoding a polypeptide including an entire sequence of the amino acid sequence as shown by SEQ ID NO: 2 or a partial sequence thereof, or a polypeptide including the polypeptide described above, wherein any of the polypeptides has an activity of a receptor capable of binding to a murine PBSF/SDF-1; a polypeptide encoded by the DNA described above, wherein the polypeptide has an activity of a receptor capable of binding to a murine PBSF/SDF-1; cells expressing the polypeptide described above and a human CD4 protein; and a method of screening an AIDS onset inhibitor or an HIV-1 infection inhibitor, characterized by the use of the cells described above. According to the present invention, there can be provided a novel murine CXC chemokine receptor gene, a method of screening an HIV-1 infection inhibitor, and the like, each of which is useful in studies of a therapeutic agent for AIDS and the functional mechanism of HIV-1 infection.

Mouse CXC chemokine receptor

A preventive and therapeutic agent for psoriasis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.

Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist

The present invention discloses a screening method for a substance, which could be a therapeutic agent for diabetes with insulin resistance through regulating a function of a molecule involved in insulin signaling pathway. More specifically, the present invention discloses a screening method for a substance having hypoglycemic activity, which is characterized by contacting a sample to STAT-induced inhibitor of STAT function-1 in the presence of insulin, and by detecting inhibitory activity of STAT-induced inhibitor of STAT function-1 by a substance in the sample, as an index.

Screening method for a substance having hypoglycemic activity by using STAT-induced inhibitor of STAT function-1

The present invention pertains to a DNA encoding a polypeptide comprising an entire sequence of the amino acid sequence as shown by SEQ ID NO:2 of Sequence Listing or a partial sequence thereof, or a polypeptide comprising the polypeptide described above, wherein any of the polypeptides has an activity of a receptor capable of binding to a murine PBSF/SDF-1; a polypeptide encoded by the DNA described above, wherein the polypeptide has an activity of a receptor capable of binding to a murine PBSF/SDF-1; cells expressing the polypeptide described above and a human CD4 protein; and a method of screening an AIDS onset inhibitor or an HIV-1 infection inhibitor, characterized by the use of the cells described above. According to the present invention, there can be provided a novel murine CXC chemokine receptor gene, a method of screening an HIV-1 infection inhibitor, and the like, each of which is useful in studies of a therapeutic agent for AIDS and the functional mechanism of HIV-1 infection.

Hydroxamic acid derivatives, process for the production thereof and drug containing the same as the active ingredient

A preventive or therapeutic agent for treating bowel disease, including Crohn's disease and ulcerative colitis, where the agent has as an active ingredient an antibody directed against IL-6 receptor which is an interleukin-6 antagonist.

Method of treating inflammatory intestinal diseases containing as the ingredient IL-6 receptors antibodies

Growing community of inventors

Tondabayashi, Japan

Tadamitsu Kishimoto